Pilot Study of Prophylactic ExVivo Costimulated Donor Leukocyte Infusion After Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 7, 2013, Pages 1094-1101

  Kumar, Anita J ^a   Hexner, Elizabeth O ^a   Frey, Noelle V ^a   Luger, Selina M ^a   Loren, Alison W ^a   Reshef, Ran ^a   Boyer, Jean ^a   Smith, Jacqueline ^a   Stadtmauer, Edward A ^a   Levine, Bruce L ^a   June, Carl H ^a   Porter, David L ^a   Goldstein, Steven C ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Alemtuzumab; Allogeneic stem cell transplantation; Costimulated donor leukocyte infusion; Donor leukocyte infusion; Leukemia; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CD28 ANTIGEN; CD3 ANTIGEN; ETANERCEPT; FLUDARABINE; GANCICLOVIR; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; EX VIVO STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HYPOTHYROIDISM; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; MALE; MYELODYSPLASTIC SYNDROME; PILOT STUDY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIATIC ARTHRITIS; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; SEPSIS; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT OUTCOME; UVEITIS; VITILIGO;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BUSULFAN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOCYTE TRANSFUSION; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; SURVIVAL ANALYSIS; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84879374195     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.04.021     Document Type: Article

References (41)

1. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
2. Martino R., de Wreede L., Fiocco M., et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone marrow transplantation 2013, 48:761-770.
3. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
4. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
5. Collins R.H., Goldstein S., Giralt S., et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000, 26:511-516.
6. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
7. Lokhorst H.M., Wu K., Verdonck L.F., et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004, 103:4362-4364.
8. Frey N.V., Porter D.L. Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Hematol 2008, 21:205-222.
9. Cardoso A.A., Schultze J.L., Boussiotis V.A., et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996, 88:41-48.
10. + T cells after allogeneic stem cell transplantation. Clin Cancer Res 2009, 15:4944-4953.
11. Porter D.L., Levine B.L., Bunin N., et al. Aphase 1 trial of donor lymphocyte infusions expanded and activated exvivo via CD3/CD28 costimulation. Blood 2006, 107:1325-1331.
12. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
13. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
14. + T cells in the absence of exogenous feeder cells. JImmunol 1997, 159:5921-5930.
15. Levine B.L., Cotte J., Small C.C., et al. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. JHematother 1998, 7:437-448.
16. Van Deerlin V.M., Leonard D.G. Bone marrow engraftment analysis after allogeneic bone marrow transplantation. Clin Lab Med 2000, 20:197-225.
17. Vonderheide R.H., June C.H. Atranslational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. Immunol Res 2003, 27:341-356.
18. Das-Gupta E.P., Russell N.H., Shaw B.E., et al. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. Biol Blood Marrow Transplant 2007, 13:724-733.
19. Poire X., van Besien K. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Exp Opin Biol Ther 2011, 11:1099-1111.
20. Choi M.S., Lim J.Y., Cho B.S., et al. The role of regulatory T cells during the attenuation of graft-versus-leukemia activity following donor leukocyte infusion in mice. Leuk Res 2011, 35:1549-1556.
21. Choi S., Reddy P. Donor Tregs suppress the good with the bad after allogeneic BMT. Leuk Res 2011, 35:1541-1542.
22. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
23. Antin J.H., Ferrara J.L. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992, 80:2964-2968.
24. Sullivan K.M., Deeg H.J., Sanders J., et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986, 67:1172-1175.
25. Sullivan K.M., Storb R., Buckner C.D., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. NEngl J Med 1989, 320:828-834.
26. Elfenbein G., Graham-Pole J., Weiner R., et al. Consequences of no prophylaxis for acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1987, 70(Suppl 1):305a.
27. Johnson B.D., Drobyski W.R., Truitt R.L. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 1993, 11:329-336.
28. Slavin S., Ackerstein A., Weiss L., et al. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 1992, 10:221-227.
29. Chakraverty R., Cote D., Buchli J., et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. JExp Med 2006, 203:2021-2031.
30. Nakamura R., Bahceci E., Read E.J., et al. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol 2001, 115:95-104.
31. Massenkeil G., Nagy M., Lawang M., et al. Reduced-intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003, 31:339-345.
32. Barrett J. Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment. Curr Opin Immunol 2006, 18:592-598.
33. Liga M., Triantafyllou E., Tiniakou M., et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 2013, 19:75-81.
34. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med 2011, 365:725-733.
35. Kalos M., Levine B.L., Porter D.L., et al. Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
36. Scholler J., Brady T.L., Binder-Scholl G., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012, 4:132ra53.
37. +-selected hematopoietic cell transplantation. Blood 2003, 102:2004-2013.
38. Rapoport A.P., Stadtmauer E.A., Aqui N., et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res 2009, 15:4499-4507.
39. Rapoport A.P., Aqui N.A., Stadtmauer E.A., et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 2011, 117:788-797.
40. Rapoport A.P., Stadtmauer E.A., Aqui N., et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005, 11:1230-1237.
41. Grupp S.A., Prak E.L., Boyer J., et al. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2012, 18:6732-6741.